Current status and progress of immunotherapy for hepatocellular carcinoma

Abstract

Abstract: Primary liver cancer (PLC) is one of the most common malignant tumors, and hepatocellular carcinoma (HCC) accounts for the majority. Traditional treatments for HCC include surgical resection, liver transplantation, transcatheter arterial chemoembolization, ablation and so on. Gradually, targeted therapy is applied to clinical treatment for HCC, which improves the patients’ survival rate. However, Effective means is still lacking for advanced HCC. In recent years, immunotherapy for HCC develops rapidly and gets more and more attention, and the relevant studies are hotspots among HCC researches. This article reviews the current status and progress of immunotherapy for HCC.

Key words: Hepatocellular carcinoma, Immunotherapy, Combined treatment

Shao Weiwei, Sun Zhen, Song Jinghai. Current status and progress of immunotherapy for hepatocellular carcinoma[J]. Electronic Journal of Liver Tumor, 2020, 7(2): 56-60.

References

[1] LLOVET JM, ZUCMAN-ROSSI J, PIKARSKY E, et al.Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2016, 2:16018.
[2] BRAY F, FERLAY J, SOERJOMATARAM I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[3] CHEN WQ, ZHENG RS, BAADE PD, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
[4] FORNER A, REIG M, BRUIX J.Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127):1301-1314.
[5] SPRINZL MF, GALLE PR.Current progress in immunotherapy of hepatocellular carcinoma[J]. J Hepatol, 2017, 66(3):482-484.
[6] BUTTERFIELD LH, RIBAS A, MENG WS, et al.T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer[J]. Clin Cancer Res, 2003, 9(16 Pt 1):5902-5908.
[7] MIZUKOSHI E, NAKAGAWA H, KITAHARA M, et al.Phase I trial of multidrug resistance-associated protein 3-derived peptide in patients with hepatocellular carcinoma[J]. Cancer Lett, 2015, 369(1):242-249.
[8] LEE JH, LEE Y, LEE M, et al.A phase Ⅰ/Ⅱa study of adjuvant immuno-therapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma[J]. Br J Cancer, 2015, 113(12):1666-1676.
[9] YUTANI S, SHIRAHAMA T, MUROYA D, et al.Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies[J]. Cancer Sci, 2017, 108(9):1732-1738.
[10] ANSARY ME, MOGAWER S, ELHAMID SA, et al.Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC[J]. J Cancer Res Clin Oncol, 2013, 139(1):39-48.
[11] MIZUKOSHI E, NAKAMOTO Y, ARAI K, et al.Enhancement of tumor-specific T-cell responses by transcatheter arterial embolization with dendritic cell infusion for hepatocellular carcinoma[J]. Int J Cancer, 2010, 126(9):2164-2174.
[12] ISHIKAWA H, BARBER GN.STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling[J]. Nature, 2008, 455(7213):674-678.
[13] ISHIKAWA H, MA Z, BARBER GN.STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity[J]. Nature, 2009, 461(7265):788-792.
[14] HEO J, REID T, RUO L, et al.Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer[J]. Nat Med, 2013, 19(3):329-336.
[15] BREITBACH CJ, BURKE J, JONKER D, et al.Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans[J]. Nature, 2011, 477(7362):99-102.
[16] KIRN DH, THORNE SH.Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer[J]. Nat Rev Cancer, 2009, 9(1):64-71.
[17] BREITBACH CJ, ARULANANDAM R, Silva ND, et al.Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans[J]. Cancer Res, 2013, 73(4):1265-1275.
[18] BERTELLI R, NERI F, TSIVIAN M, et al.Endolymphatic immunotherapy in inoperable hepatocellular carcinoma[J]. Transplant Proc, 2008, 40(6):1913-1915.
[19] LI PY, DU Q, CAO ZX, et al.Interferon-γ induces autophagy with growth inhibition and cell death in human hepatocellular carcinoma (HCC) cells through interferon-regulatory factor-1 (IRF-1)[J]. Cancer Lett, 2012, 314(2):213-222.
[20] SUN HC, TANG ZY, WANG L, et al.Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial[J]. J Cancer Res Clin Oncol, 2006, 132(7):458-465.
[21] LEE DW, BARRETT DM, MACKALL C, et al.The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer[J]. Clin Cancer Res, 2012, 18(10):2780-2790.
[22] SANGRO B, GOMEZ-MARTIN C, DE LA MATA M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C[J]. J Hepatol, 2013, 59(1):81-88.
[23] DUFFY AG, ULAHANNAN SV, MAKOROVA-RUSHER O, et al.Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma[J]. J Hepatol, 2017, 66(3):545-551.
[24] EL-KHOUEIRY AB, SANGRO B, YAU T, et al.Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088):2492-2502.
[25] ZHU AX, FINN RS, EDELINE J, et al.Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial[J]. Lancet Oncol, 2018, 19(7):940-952.
[26] YAU T, PARK JW, FINN RS, et al. CheckMate 459: a randomized, multi-center phaseⅢ study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)[J]. Presented at the2019 Congress of the European Society of Medical Oncology, Barcelona, September 27-October 1, 2019. abstract.
[27] FINN RS, RYOO BY, MERLE P, et al. Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs. best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC)[J]. J Clin Oncol 37, 2019 (suppl; abstr 4004).
[28] QIN SK, REN ZG, MENG ZQ, et al.Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial[J]. Lancet Oncol, 2020, 21(4):571-580.
[29] FINN RS, QIN SK, IKEDA M, et al.Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med , 2020, 382:1894-905.
[30] JUNG NC, LEE JH, CHOI HJ, et al.Dendritic Cell Immunotherapy Combined with Cytokine-Induced Killer Cells Effectively Suppresses Established Hepatocellular Carcinomas in Mice[J]. Immunol Invest, 2016, 45(6):553-565.
[31] LI YC, ZHAO L, WU JP, et al.Cytokine-induced killer cell infusion combined with conventional treatments produced better prognosis for hepatocellular carcinoma patients with barcelona clinic liver cancer B or earlier stage: A systematic review and meta-analysis[J]. Cytotherapy, 2016, 18(12):1525-1531.
[32] GRUPP SA, KALOS M, BARRETT D, et al.Chimeric antigen receptor-modified T cells for acute lymphoid leukemia[J]. N Engl J Med, 2013, 368(16):1509-1518.
[33] ARRESE M, CABRERA D, KALERGIS AM, et al.Innate Immunity and Inflammation in NAFLD/NASH[J]. Dig Dis Sci, 2016, 61(5):1294-1303.
[34] PATEL SA, MINN AJ.Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies[J]. Immunity, 2018, 48(3):417-433.
[35] ARIZUMI T, UESHIMA K, MINAMI T, et al.Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma[J]. Liver Cancer, 2015, 4(4):253-262.
[36] TIAN L, GOLDSTEIN A, WANG H, et al.Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming[J]. Nature, 2017, 544(7649):250-254.
[37] LARKIN J, CHIARION-SILENI V, GONZALEZ R, et al.Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma[J]. N Engl J Med, 2015, 373(1):23-34.
[38] KUDO M. Immuno-Oncology in Hepatocellular Carcinoma:2017 Update[J]. Oncology, 2017, 93 Suppl1:147-159.